sabato, 2 maggio 2026

Notizie Newsletter

Individual Patient Data Meta-Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer

In the CLASSIC and MAGIC trials, microsatellite instability (MSI)-high status was a favorable prognostic and potential negative predictive factor for neoadjuvant/adjuvant chemotherapy in resectable gastric cancer (GC). Given the low prevalence of MSI-high status in GC and ...
Leggi tutto

Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609

Phase III adjuvant trials have reported significant benefits in both relapse-free survival (RFS) and overall survival (OS) for high-dose interferon alfa (HDI) and ipilimumab at 10 mg/kg (ipi10). E1609 evaluated the safety and efficacy of ipilimumab at 3 mg/kg (ipi3) and ...
Leggi tutto

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

Denosumab is a fully human monoclonal antibody that binds to, and inhibits, the receptor activator of RANKL (TNFSF11) and might affect breast cancer biology, as shown by preclinical evidence. We aimed to assess whether denosumab combined with standard-of-care adjuvant or ...
Leggi tutto

Frontline Pembrolizumab Regimens Receive Japanese Approval in Head and Neck Cancer

December 20, 2019 - Japan’s Pharmaceuticals and Medical Devices Agency has granted approval to frontline pembrolizumab as monotherapy and in combination with chemotherapy for the treatment of patients with recurrent or distant metastatic head and neck cancer. ...
Leggi tutto

Frontline Pembrolizumab/Axitinib Approved in Japan for Advanced RCC

December 20, 2019 - Japan’s Pharmaceuticals and Medical Devices Agency has approved the combination of pembrolizumab and axitinib for the first-line treatment of patients with radically unresectable or metastatic renal cell carcinoma (RCC). The approval is based on ...
Leggi tutto

Everett E. Vokes, MD, FASCO, Elected ASCO President for 2021-2022 Term

December 17, 2019 - The American Society of Clinical Oncology (ASCO) has elected Everett E. Vokes, MD, FASCO, a long-time member and volunteer, to serve as its President for the term beginning in June 2021. He will take office as President-Elect during the ASCO Annual Meeting ...
Leggi tutto

Ten Oncology Practices in Underserved Communities Receive Funding to Participate in Quality Improvement Programs

December 18, 2019 - Ten oncology practices from rural and urban centers in the U.S. that primarily treat underserved populations have received grant funding to participate in the American Society of Clinical Oncology’s (ASCO) Quality Oncology Practice Initiative (QOPI®) ...
Leggi tutto

FDA Approval Sought for Ripretinib for Advanced GIST

December 16, 2019 - A new drug application (NDA) has been submitted to the FDA for ripretinib for use as a treatment for patients with advanced gastrointestinal stromal tumors (GIST) who have previously received treatment with imatinib, sunitinib, and regorafenib. The application ...
Leggi tutto

FDA Approves Enzalutamide for Metastatic Castration-Sensitive Prostate Cancer

December 17, 2019 - The FDA has approved a supplemental new drug application for enzalutamide for the treatment of patients with metastatic castration-sensitive prostate cancer. The approval is based on findings from the phase III ARCHES trial, in which the median radiographic ...
Leggi tutto

FDA Panel Backs Maintenance Olaparib for Metastatic Pancreatic Cancer

December 17, 2019 - The FDA’s Oncologic Drugs Advisory Committee (ODAC) voted 7 to 5 in favor of olaparib tablets for an indication as a maintenance treatment of adult patients with deleterious or suspected deleterious BRCA-mutant metastatic pancreatic adenocarcinoma ...
Leggi tutto